The Commission is rushing to present the Critical Medicines Act on 11 March in Strasbourg, raising concerns among European pharma companies about the lack of proper evaluation. EUCOPE urges reconsideration of the haste, while Bayer and Roche highlight the need for a thorough impact assessment before publication. The Act aims to address severe shortages of essential medicines in the EU, but industry leaders argue that the urgency does not justify bypassing assessments.